Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Share-based Compensation (2016 - 2025)

Perspective Therapeutics' Share-based Compensation history spans 16 years, with the latest figure at $2.2 million for Q3 2025.

  • For Q3 2025, Share-based Compensation rose 10.45% year-over-year to $2.2 million; the TTM value through Sep 2025 reached $8.7 million, up 88.88%, while the annual FY2024 figure was $5.4 million, 44.11% up from the prior year.
  • Share-based Compensation for Q3 2025 was $2.2 million at Perspective Therapeutics, down from $2.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.4 million in Q2 2025 and bottomed at $94000.0 in Q1 2021.
  • The 5-year median for Share-based Compensation is $672000.0 (2022), against an average of $977105.3.
  • The largest YoY upside for Share-based Compensation was 601.18% in 2021 against a maximum downside of 42.47% in 2021.
  • A 5-year view of Share-based Compensation shows it stood at $180000.0 in 2021, then skyrocketed by 273.33% to $672000.0 in 2022, then skyrocketed by 91.67% to $1.3 million in 2023, then soared by 59.94% to $2.1 million in 2024, then increased by 4.66% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Share-based Compensation are $2.2 million (Q3 2025), $2.4 million (Q2 2025), and $2.1 million (Q1 2025).